Physician profile
Hiba Sayed
NPI 1487158663
$1,188.09
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $549 · 2023: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.19 | 2022-2023 | Rybelsus, Ozempic, Saxenda |
| Abbvie INC. | $196.46 | 2021-2023 | Ubrelvy, Qulipta |
| Pfizer INC. | $172.31 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.63 | 2022 | |
| Glaxosmithkline, LLC. | $87.54 | 2022-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $87.30 | 2022-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Exact Sciences Corporation | $65.37 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $48.20 | 2021-2023 | Mounjaro, Emgality, Reyvow |
| Astrazeneca Pharmaceuticals Lp | $30.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.36 | 2023 | Xarelto |
| Ibsa Pharma INC. | $24.51 | 2022 | |
| Upsher-Smith Laboratories LLC | $24.48 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.28 | 2023 | Quviviq |
| Eisai INC. | $21.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.05 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $19.73 | 2022 | |
| Grifols USA, LLC | $17.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiba Sayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.